1.Combined application of antimicrobial peptide LL-37 and zoledronic acid modulates osteoclast function under in vitro inflammatory conditions
Xin XI ; Chao SHI ; Zheqing AN ; Hangjiyun LI ; Xiaoyan LIU ; Wei HONG ; Jian LIAO
Acta Universitatis Medicinalis Anhui 2026;61(10):1784-1795
ObjectiveTo explore the inhibitory effects of LL-37 combined with zoledronic acid on the differentiation and function of inflammatory osteoclasts induced by receptor activator of nuclear factor-κB ligand (RANKL) and Lipopolysaccharide (LPS), as well as its activity against Porphyromonas gingivalis (P.gingivalis), via network pharmacology, molecular docking, and in vitro experiments. MethodsThe targets of LL-37 and zoledronic acid (ZA) were retrieved from TargetNet and Similarity Ensemble Approach (SEA) databases, and implant peri-implantitis-related targets were screened out via GeneCards and Online Mendelian Inheritance in Man (OMIM) databases. The Venn online tool was used to acquire drug-disease intersecting targets, followed by the construction of protein-protein interaction network as well as enrichment analysis and molecular docking. Afterwards, tartrate-resistant acid phosphatase (TRAP) staining and RT-qPCR were adopted to compare the osteoclast differentiation in RAW264.7 cell models induced by RANKL alone, LPS alone and their combination in vitro. Finally, CCK-8 assay and microbroth dilution method were used to confirm the safe concentration ranges of LL-37 and ZA. Disc diffusion method, TRAP staining, RT-qPCR, ELISA and Western blot were applied to explore the superior effects of combined administration of LL-37 and ZA over single drug use in inhibiting P.gingivalis, suppressing osteoclast activity and alleviating inflammatory responses. ResultsA total of 28 potential intersecting targets were screened, among which CASP3, STAT3, MMP3, SIRT1 and NOS3 were identified as core targets. Enrichment analyses revealed that LL-37 combined with ZA might regulate the pathological progression of peri-implantitis via multiple targets and signaling pathways. TRAP staining and RT-qPCR results demonstrated that RAW264.7 cells induced by RANKL combined with LPS established a better in vitro inflammatory osteoclast model compared with single induction mode. In vitro experiments verified that combined treatment with LL-37 and ZA exerted more prominent effects on inhibiting osteoclast differentiation and formation and downregulating the expression of inflammatory factors than monotherapy. Disc diffusion assay further confirmed that the combination possessed favorable antibacterial activity. ConclusionUnder inflammatory conditions, combined administration of LL-37 and ZA can effectively inhibit bacterial growth, osteoclast activity and inflammatory responses.

Result Analysis
Print
Save
E-mail